-
公开(公告)号：US20240190995A1
公开(公告)日：2024-06-13
申请号：US18383464
申请日：2023-10-24
发明人： Jinxiang Zhou , Graham Temples
CPC分类号： C07K16/34 , A61K35/16 , B01D15/203 , B01D15/3809 , B01J20/264 , B01J20/28033 , B01J20/3219 , B01J20/3278
摘要： Separation media that includes a support substrate and a plurality of separation ligands immobilized on the support substrate. The plurality of separation ligands include an affinity capable of recognizing and binding to blood type antigen recognizing domain. Methos of making the separation media and methods of using the separation media.
-
公开(公告)号：US11945857B2
公开(公告)日：2024-04-02
申请号：US17126396
申请日：2020-12-18
CPC分类号： C07K16/1278 , C07K16/1018 , C07K16/1063 , C07K16/34 , C07K2317/14 , C07K2317/20 , C07K2317/33 , C07K2317/35 , C07K2317/76
摘要： Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
-
公开(公告)号：US09989537B2
公开(公告)日：2018-06-05
申请号：US14431424
申请日：2013-10-01
申请人： LU License AB
发明人： Jill R. Storry , Magnus Jöud , Björn Nilsson , Martin L. Olsson
CPC分类号： G01N33/6854 , A61K35/18 , C07K7/08 , C07K14/00 , C07K16/34 , C07K2317/34 , C12N15/1138 , C12N2310/14 , C12N2310/531 , C12Q1/6827 , C12Q1/6881 , C12Q2600/106 , C12Q2600/156 , G01N33/80
摘要： The present invention relates to methods and tools for discriminating between Vel negative and Vel positive phenotypes. The invention is thus useful for determining Vel blood group status of individuals about to receive blood transfusion.
-
公开(公告)号：US20170210821A1
公开(公告)日：2017-07-27
申请号：US15327629
申请日：2015-07-21
申请人： Bloodworks
IPC分类号： C07K16/34
CPC分类号： C07K16/34 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/33 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods of using antibodies that are able to recognize single amino acid polymorphisms in a protein are provided. Compositions are disclosed which may be used for blood typing or to block hemolytic transfusion reactions and/or hemolytic disease of the fetus and newborn.
-
公开(公告)号：US20170121422A1
公开(公告)日：2017-05-04
申请号：US15300656
申请日：2015-03-31
申请人： UNIVERSITETET I TROMSØ - NORGES ARKTISKE UNIVERSITET , UNIVERSITY HOSPITAL OF NORTH NORWAY , NORINNOVA TECHNOLOGY TRANSFER AS
发明人： Terje MICHAELSEN , Oistein IHLE , Tor Brynjar STUGE , Anne HUSEBEKK , Heidi TILLER , Mariana EKSTEEN , Bjorn Ragnar SKOGEN
CPC分类号： C07K16/34 , C07K16/2848 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/56 , C07K2317/565 , C07K2317/70 , C07K2317/76 , C07K2317/92 , G01N33/6893 , G01N2333/705 , G01N2800/38
摘要： The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
-
6.发明申请公开(公告)号：US20160200830A1
公开(公告)日：2016-07-14
申请号：US14903156
申请日：2014-07-08
发明人： Fang Liang ZHANG , Jianbing ZHANG , Shu WU
IPC分类号： C07K16/34
CPC分类号： C07K16/34 , C07K16/18 , C07K2317/22 , C07K2317/565 , C07K2317/569 , C07K2317/94 , C07K2319/00 , C07K2319/30
摘要： Novel antibodies, such as single domain antibodies (sdAbs), or fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are described.
摘要翻译： 描述了特异性结合转铁蛋白的新型抗体，例如单结构域抗体（sdAb）或其片段。 描述了使用针对转铁蛋白的抗体或其片段增加血清中靶蛋白的半衰期的组合物，方法和系统。
-
公开(公告)号：US20150307624A1
公开(公告)日：2015-10-29
申请号：US14702143
申请日：2015-05-01
发明人： Dominique Bourel , Sylvie Jorieux , Christophe de Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
CPC分类号： C07K16/34 , A61K2039/505 , C07K16/18 , C07K16/2833 , C07K2317/14 , C07K2317/41 , C07K2317/732 , Y02A50/412
摘要： The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
摘要翻译： 本发明涉及在所选细胞系中产生的人或人源化嵌合单克隆抗体的用途，所述抗体导致高ADCC活性以及细胞因子和白细胞介素的高分泌，用于治疗所谓的弱反应患者的人群 显示CD16 FCGR3A-158F纯合子或FCGR3A-158V / F杂合子多态性。
-
公开(公告)号：US20150072368A1
公开(公告)日：2015-03-12
申请号：US14375503
申请日：2013-02-08
CPC分类号： C07K16/2887 , C07K16/34 , C12N15/85 , C12N2830/007 , C12N2830/15 , C12N2830/42 , C12N2830/60 , C12N2830/85
摘要： Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.
摘要翻译： 可用于表达载体的新型转录单位。 转录单元允许产生其生产力增益不与特定抗原靶抗体相关的抗体，因此通过外推到给定的重组蛋白质，也不与培养基连接。
-
公开(公告)号：US20140044723A1
公开(公告)日：2014-02-13
申请号：US13949515
申请日：2013-07-24
发明人： Hiroshi Takayama , Kamon Shirakawa , Shoji Furusako , Yoshitaka Hosaka , Tomokazu Matsusue , Katsuki Naitoh , Yumi Hotta , Tetsushi Kawahara , Motoyasu Honda
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/2803 , C07K16/34 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
摘要翻译： 本发明提供具有以下特征的抗体，其活性片段或其衍生物：a）其特异性结合人血小板膜糖蛋白VI（GPVI）; b）激活血小板和/或在体内诱导血小板减少症的功能低; 和c）它通过与血小板接触至少部分地消耗血小板膜上的GPVI。
-
公开(公告)号：US20140017243A1
公开(公告)日：2014-01-16
申请号：US13930070
申请日：2013-06-28
发明人： Dominique Bourel , Sylvie Jorieux , Christophe de Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： C07K16/18
CPC分类号： C07K16/34 , A61K2039/505 , C07K16/18 , C07K16/2833 , C07K2317/14 , C07K2317/41 , C07K2317/732 , Y02A50/412
摘要： The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
摘要翻译： 本发明涉及在所选细胞系中产生的人或人源化嵌合单克隆抗体的用途，所述抗体导致高ADCC活性以及细胞因子和白细胞介素的高分泌，用于治疗所谓的弱反应患者的人群 显示CD16 FCGR3A-158F纯合子或FCGR3A-158V / F杂合子多态性。
-
-
-
-
-
-
-
-
-
搜索结果
272 条记录 (耗时 0.039 秒)
